PROLACTIN RESPONSE AS AN INDEX OF DOPAMINERGIC RECEPTOR FUNCTION IN PARKINSONS-DISEASE - CORRELATION WITH CLINICAL FINDINGS AND THERAPEUTIC RESPONSE
PROLACTIN RESPONSE AS AN INDEX OF DOPAMINERGIC RECEPTOR FUNCTION IN PARKINSONS-DISEASE - CORRELATION WITH CLINICAL FINDINGS AND THERAPEUTIC RESPONSE
复制标题
DOI：
10.1007/bf01664010
复制
发表时间：
1981-01-01
影响因子：
3.3
通讯作者：
ROCCO, A
中科院分区：
文献类型：
--
作者：
AGNOLI, A;BALDASSARRE, M;ROCCO, A
在13名未经治疗的帕金森病患者中，在用L-多巴+卡比多巴治疗15天之前和之后，评价了催乳素的昼夜节律。第24分泌模式与对照组无显著差异。左旋多巴+卡比多巴治疗不会改变基础昼夜催乳素（PRL）节律。结果提示，未经治疗的帕金森病患者（PP）的结节漏斗部多巴胺能系统（TIDA）和PRL分泌是保守的，在长期左旋多巴+卡比多巴治疗过程中，21例PP的基础PRL水平与临床症状的严重程度相关。研究了单剂量阿扑吗啡、溴隐亭、麦角脲和氟哌啶醇对21例PP患者血清PRL水平的影响，将其分为“应答者”和“无应答者”两组。氟哌啶醇诱导血清PRL的增强，多巴胺能药物，阿扑吗啡，溴隐亭和麦角乙脲抑制基础PRL分泌。似乎帕金森病中的TIDA系统没有显著改变，即使在对L-多巴治疗的“无应答者”中呈现出明显较慢的应答。我们还评估了L-Dopa、L-Dopa +卡比多巴、溴隐亭、麦角乙脲、诺米芬辛和丙炔苯丙胺对6种PP中生长激素分泌的影响。多巴胺能药物的内分泌效应与对照组相比显示出轻度升高，表明多巴胺（DA）对生长激素（GH）的控制发生了重要改变。
Circadian rhythms of prolactin have been evaluated in thirteen untreated parkinsonian patients before and after 15 days of treatment with L-Dopa + carbidopa. The 24th secretory pattern was not significatively different from that observed in controls. The L-Dopa + carbidopa therapy does not change the basal circadian prolactin (PRL) rhythm. These results suggest that the tubero-infundibular dopaminergic system (TIDA) and the PRL secretion are conserved in untreated parkinsonian patients (PP).During chronic L-Dopa + carbidopa therapy, the basal PRL levels, evaluated in 21 PP, showed a correlation with the severity of clinical features. The effects of single doses of apomorphine, bromocriptine, lisuride and haloperidol, were studied on serum levels of PRL in 21 PP divided in two groups of “responders” and “non-responders”. Haloperidol induced an enhancement of serum PRL; the dopaminergic drugs, apomorphine, bromocriptine and lisuride inhibited basal PRL secretion. It seems that the TIDA system, in Parkinson disease is not significatively altered, even though presenting a remarkably slower response in “non-responders” to L-Dopa therapy. We also evaluated the effect of L-Dopa, L-Dopa + carbidopa, bromocriptine, lisuride, nomifensine and deprenyl on growth hormone secretion in six PP. The endocrine effects of dopaminergic drugs show a mild rise in comparison with controls suggesting an important alteration in the dopamine (DA) control of growth hormone (GH).